133683-10-0

Basic information

• Product Name: (S)-2-[(1,4-Dioxa-8-aza-spiro[4.5]decane-8-carbonyl)-amino]-3-phenyl-propionic acid benzyl ester
• Synonyms: (S)-2-[(1,4-Dioxa-8-aza-spiro[4.5]decane-8-carbonyl)-amino]-3-phenyl-propionic acid benzyl ester
• CAS NO: 133683-10-0
• Molecular Weight: 424.497
• Mol File: 133683-10-0.mol

Chemical Properties

• CAS DataBase Reference: (S)-2-[(1,4-Dioxa-8-aza-spiro[4.5]decane-8-carbonyl)-amino]-3-phenyl-propionic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[(1,4-Dioxa-8-aza-spiro[4.5]decane-8-carbonyl)-amino]-3-phenyl-propionic acid benzyl ester(133683-10-0)
• EPA Substance Registry System: (S)-2-[(1,4-Dioxa-8-aza-spiro[4.5]decane-8-carbonyl)-amino]-3-phenyl-propionic acid benzyl ester(133683-10-0)

Safety Data

• Hazardous Substances Data: 133683-10-0(Hazardous Substances Data)

Upstream product

• 107-21-1 ethylene glycol 

Downstream Products

• 133683-11-1 (S)-2-[(1,4-Dioxa-8-aza-spiro[4.5]decane-8-carbonyl)-amino]-3-phenyl-propionic acid 
• 198989-67-2 1,4-Dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid ((S)-1-{[(S)-1-((1S,2S,4S)-1-cyclohexylmethyl-2,4-dihydroxy-5-methyl-hexylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-methyl-carbamoyl}-2-phenyl-ethyl)-amide 

Relevant articles and documents

Novel renin inhibitors containing (2S,3S,5S)-2-amino-1-cyclohexyl-6- methyl-3,5-heptanediol fragment as a transition-state mimic at the P1-P1' cleavage site

A series of renin inhibitors containing the (2S,3S,5S)-2-amino-1- cyclohexyl-6-methyl-3,5-heptanediol (2-amino-3,5-anti-diol) fragment as a novel transition-state mimic was synthesized, and their biological activities were evaluated. All of the synthesized compounds containing the 2-amino-3,5- anti-diol fragment at the P1-P1' position showed high in vitro renin- inhibitory activity with IC50 values in the 10-8-10-10 M range, and most of them caused a reduction of blood pressure when administered orally to salt-depleted, conscious marmosets. The inhibitor (29) with the 4- hydroxypiperidine residue at the P4 position showed the highest activity in terms of both potency and duration of the blood pressure-lowering effect.